Game-Changer in HIV Prevention: FDA Approves Yeztugo

The U.S. FDA approved Gilead Sciences' lenacapavir, under the brand name Yeztugo, for HIV prevention. This twice-yearly injection offers new hope to curb the epidemic. While its efficacy is celebrated, concerns about accessibility and affordability persist. Gilead aims for widespread rollout in collaboration with global partners.

The United States Food and Drug Administration has granted approval to Gilead Sciences' lenacapavir, known commercially as Yeztugo, for the prevention of HIV. This novel twice-yearly injection presents a promising option for adults and adolescents at high risk of contracting HIV, potentially marking a significant step in controlling the 44-year-old epidemic.

Priced at $28,218 annually in the U.S., Yeztugo has demonstrated near 100% effectiveness in trials. Advocacy groups are calling for the drug to be affordable and accessible. Gilead is negotiating insurance coverage and will provide assistance programs for the underinsured and uninsured populations.

Despite high price concerns, lenacapavir's supplemental potential to daily PrEP pills offers crucial benefits. The approval marks a milestone, with Gilead planning rapid launches nationwide and globally. The broader rollout is in line with efforts to address HIV spread, particularly in highly affected regions like Africa.

(With inputs from agencies.)